Q2 EPS Forecast for Aardvark Therapeutics Boosted by Analyst

Aardvark Therapeutics, Inc. (NASDAQ:AARD) – Stock analysts at HC Wainwright boosted their Q2 2027 EPS estimates for Aardvark Therapeutics in a research note issued on Monday, October 26th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.43) for the quarter, up from their previous forecast of ($0.44). HC Wainwright currently has a “Neutral” rating and a $2.00 target price on the stock. The consensus estimate for Aardvark Therapeutics’ current full-year earnings is ($3.05) per share. HC Wainwright also issued estimates for Aardvark Therapeutics’ Q3 2027 earnings at ($0.40) EPS, Q4 2027 earnings at ($0.43) EPS and FY2027 earnings at ($1.70) EPS.

Several other research analysts also recently commented on the stock. Royal Bank Of Canada set a $2.50 price objective on shares of Aardvark Therapeutics in a report on Friday. BTIG Research restated a “neutral” rating on shares of Aardvark Therapeutics in a research report on Monday, October 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aardvark Therapeutics in a report on Tuesday, September 29th. UBS Group set a $4.00 target price on Aardvark Therapeutics in a research report on Monday, October 19th. Finally, Oppenheimer lowered Aardvark Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $11.28.

Aardvark Therapeutics Stock Performance

Shares of NASDAQ AARD opened at $1.30 on Wednesday. The company has a market cap of $28.45 million, a P/E ratio of -0.40 and a beta of 3.80. The firm’s fifty day moving average is $5.06 and its two-hundred day moving average is $6.62. Aardvark Therapeutics has a 52-week low of $0.93 and a 52-week high of $16.60.

Aardvark Therapeutics (NASDAQ:AARD) last issued its earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.21.

Institutional Investors Weigh In On Aardvark Therapeutics

Hedge funds have recently bought and sold shares of the business. Susquehanna International Group LLP bought a new position in Aardvark Therapeutics during the second quarter valued at $138,000. J. Goldman & Co LP purchased a new position in shares of Aardvark Therapeutics in the 2nd quarter worth $233,000. Ieq Capital LLC bought a new stake in shares of Aardvark Therapeutics in the 2nd quarter worth about $221,000. BlackRock Inc. bought a new stake in shares of Aardvark Therapeutics in the 2nd quarter worth about $1,077,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Aardvark Therapeutics in the 1st quarter worth about $267,000.

Insider Buying and Selling at Aardvark Therapeutics

In related news, insider Nelson Sun sold 62,000 shares of the firm’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $5.18, for a total value of $321,160.00. Following the completion of the transaction, the insider directly owned 35,475 shares of the company’s stock, valued at approximately $183,760.50. This trade represents a 63.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 17.80% of the company’s stock.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing oral therapies for metabolic diseases and other conditions involving appetite regulation. The company’s approach is based on activating bitter taste receptors in the gastrointestinal tract to stimulate the release of gut hormones associated with satiety and metabolic control.

Aardvark’s lead investigational product, ARD-101, is an orally administered, broad-spectrum bitter taste receptor agonist.